SWShuai Wang

Shuai Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shuai Wang has a total of 140 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Ketone reduction drives major circulating metabolites of GDC-8264 in humans

    by Shuai Wang, Susan Wong, Antonio DiPasquale, Shuguang Ma, Allen Y. Hong, Teresa Mulder, Simon Wong, Arturo L. Aguirre, Caitlin Chua, Liuxi Chen, et al.


  • Open Access

    Guided Sample Pooling in Human Mass Balance Studies: A Recommended Strategic Decision Framework

    by Filip Cuyckens, Wenying Li, Adam M. Auclair, Kenneth C. Cassidy, Cathy Cantalloube, Gary Collins, Alexander D. James, Chris Gibson, Ulrike Glaenzel, Felix Huth, et al.

    Radiolabeled human mass balance studies are crucial for identifying circulating metabolites and understanding drug absorption, excretion, and clearance pathways. Metabolite profiling involves quantifying all drug‐related entities, including parent drug and metabolites in plasma and excreta, using extended liquid chromatography methods coupled with detection through scintillation counting, accelerator mass spectrometry, or non‐radiolabeled approaches. Given the labor‐intensive nature of sample extraction and analysis, we propose a new paradigm that maximizes gathering information through sample pooling strategies. Our proposal introduces sample pooling strategies by integrating both individual and pooled sample schemes, simplifying decisions, and consolidating existing knowledge into a cohesive document. This aligns with the low statistical power typically associated with mass balance studies that dose six to eight subjects. In metabolite profiling, it is common practice to pool samples either from the limited number of subjects participating in a human mass balance study or from different time points of sample collection. This approach improves efficiency while preserving data integrity. Pooling reduces resource constraints and enables the concentration of samples with relatively low radioactivity levels, resulting in higher quality metabolite profiles. Nevertheless, there are situations when analyzing samples from individual subjects or time points may be preferred. This proposal presents guidance and decision trees designed to facilitate informed decisions about sample pooling to maximize data quality of metabolite profiling in human mass balance studies while efficiently managing resources. These recommendations stem from discussions within the mass balance working group of the IQ Consortium.


  • Beyond single-dose human mass balance study: minimizing subject confinement and enabling true steady-state assessment with a novel multiple-dose design proposal

    by Shuai Wang, Weiping Zhao, Sandhya Mandlekar, Lin Pan, Donglu Zhang, Cyrus Khojasteh, Cornelis E.C.A. Hop


  • In vitro metabolism of targeted covalent inhibitors and their thiol conjugates by gut microbiome from rats, mice, and humans

    by Ting-Jia Gu, Jingwei Cai, Alexis Auster, Elizabeth Torres, Donglu Zhang, S. Cyrus Khojasteh, Shuai Wang


  • Bioactivation and reactivity research advances – 2023 year in review

    by Shuai Wang, Upendra A. Argikar, Maria Chatzopoulou, Sungjoon Cho, Rachel D. Crouch, Deepika Dhaware, Ting-Jia Gu, Carley J. S. Heck, Kevin M. Johnson, Amit S. Kalgutkar, et al.

    Advances in the field of bioactivation have significantly contributed to our understanding and prediction of drug-induced liver injury (DILI). It has been established that many adverse drug reactions, including DILI, are associated with the formation and reactivity of metabolites. Modern methods allow us to detect and characterize these reactive metabolites in earlier stages of drug development, which helps anticipate and circumvent the potential for DILI. Improved in silico models and experimental techniques that better reflect in vivo environments are enhancing predictive capabilities for DILI risk. Further, studies on the mechanisms of bioactivation, including enzyme interactions and the role of individual genetic differences, have provided valuable insights for drug optimizations. Cumulatively, this progress is continually refining our approaches to drug safety evaluation and personalized medicine.Shuai Wang and Cyrus Khojasteh, on behalf of the authors.


  • Biotransformation research advances – 2023 year in review

    by S. Cyrus Khojasteh, Upendra A. Argikar, Maria Chatzopoulou, Lionel Cheruzel, Sungjoon Cho, Deepika Dhaware, Kevin M. Johnson, Amit S. Kalgutkar, Joyce Liu, Bin Ma, et al.

    This annual review marks the eighth in the series starting with Baillie et al. (2016) Our objective is to explore and share articles which we deem influential and significant in the field of biotransformation. Its format is to highlight important aspects captured in synopsis followed by a commentary with relevant figure and references.


  • Metabolism of new drug modalities research advances – 2023 year in review

    by Bin Ma, Upendra A Argikar, Lionel Cheruzel, Sungjoon Cho, Simon Hauri, Kevin M Johnson, Joyce Liu, Simone Schadt, Shuai Wang, S. Cyrus Khojasteh

    With contributions from colleagues across academia and industry, we have put together the annual reviews of research advances on drug biotransformation and bioactivation since 2016 led by Cyrus Khojasteh. While traditional small molecules and biologics are still predominant in drug discovery, we start to notice a paradigm shift toward new drug modalities (NDMs) including but not limited to peptide and oligonucleotide therapeutics, protein degraders (heterobifunctional degraders and molecule glues), conjugated drugs and covalent inhibitors. The readers can learn more on each new drug modality from several recent comprehensive reviews (Blanco et al., 2022; Hillebrand et al., 2024; Phuna et al., 2024). Based on this trend, we put together this stand-alone review branched from our previous efforts (Baillie et al., 2016; Khojasteh et al., 2023) with a focus on the metabolism of NDMs. We collected 11 articles which exemplify recent discoveries and perspectives in this field.


  • Open Access

    Increasing the Throughput and Reproducibility of Activity-Based Proteome Profiling Studies with Hyperplexing and Intelligent Data Acquisition

    by Hanna G. Budayeva, Taylur P. Ma, Shuai Wang, Meena Choi, Christopher M. Rose

    Intelligent data acquisition (IDA) strategies, such as a real-time database search (RTS), have improved the depth of proteome coverage for experiments that utilize isobaric labels and gas phase purification techniques (i.e., SPS-MS3). In this work, we introduce inSeqAPI, an instrument application programing interface (iAPI) program that enables construction of novel data acquisition algorithms. First, we analyze biotinylated cysteine peptides from ABPP experiments to demonstrate that a real-time search method within inSeqAPI performs similarly to an equivalent vendor method. Then, we describe PairQuant, a method within inSeqAPI designed for the hyperplexing approach that utilizes protein-level isotopic labeling and peptide-level TMT labeling. PairQuant allows for TMT analysis of 36 conditions in a single sample and achieves ∼98% coverage of both peptide pair partners in a hyperplexed experiment as well as a 40% improvement in the number of quantified cysteine sites compared with non-RTS acquisition. We applied this method in the ABPP study of ligandable cysteine sites in the nucleus leading to an identification of additional druggable sites on protein- and DNA-interaction domains of transcription regulators and on nuclear ubiquitin ligases.


  • The Importance of Tracking “Missing” Metabolites: How and Why?

    by Shuai Wang, T. Eric Ballard, Lisa J. Christopher, Robert S. Foti, Chungang Gu, S. Cyrus Khojasteh, Joyce Liu, Shuguang Ma, Bin Ma, R. Scott Obach, et al.

    Technologies currently employed to find and identify drug metabolites in complex biological matrices generally yield results that offer a comprehensive picture of the drug metabolite profile. However, drug metabolites can be missed or are captured only late in the drug development process. This could be due to a variety of factors, such as metabolism that results in partial loss of the molecule, covalent bonding to macromolecules, the drug being metabolized in specific human tissues, or poor ionization in a mass spectrometer. These scenarios often draw a great deal of attention from chemistry, safety assessment, and pharmacology. This review will summarize scenarios of missing metabolites, why they are missing, and associated uncovering strategies from deeper investigations. Uncovering previously missed metabolites can have ramifications in drug development with toxicological and pharmacological consequences, and knowledge of these can help in the design of new drugs.


  • Bioactivation and reactivity research advances – 2022 year in review‡

    by Shuai Wang, Upendra A. Argikar, Lionel Cheruzel, Sungjoon Cho, Rachel D. Crouch, Deepika Dhaware, Carley J. S. Heck, Kevin M. Johnson, Amit S. Kalgutkar, Lloyd King, et al.

    With the 50th year mark since the launch of Drug Metabolism and Disposition journal, the field of drug metabolism and bioactivation has advanced exponentially in the past decades (Guengerich 2023). This has, in a major part, been due to the continued advances across the whole spectrum of applied technologies in hardware, software, machine learning (ML), and artificial intelligence (AI). LC-MS platforms continue to evolve to support key applications in the field, and automation is also improving the accuracy, precision, and throughput of these supporting assays. In addition, sample generation and processing is being aided by increased diversity and quality of reagents and bio-matrices so that what is being analyzed is more relevant and translatable. The application of in silico platforms (applied software, ML, and AI) is also making great strides, and in tandem with the more traditional approaches mentioned previously, is significantly advancing our understanding of bioactivation pathways and how these play a role in toxicity. All of this continues to allow the area of bioactivation to evolve in parallel with associated fields to help bring novel or improved medicines to patients with urgent or unmet needs. Shuai Wang and Cyrus Khojasteh, on behalf of the authors.